MW Microbes World Microbial Science & Research

Introduction

Escherichia coli, commonly known as E. coli, is one of the most extensively studied bacteria in microbiology. It is a Gram-negative, rod-shaped bacterium belonging to the family Enterobacteriaceae and is commonly found in the intestinal tract of humans and other warm-blooded animals. Most strains live in the gut without causing disease, but some possess specialized virulence factors that allow them to cause intestinal infections, urinary tract infections, bloodstream infections, meningitis, and diseases in animals.

The importance of E. coli extends far beyond infectious diseases. Scientists have used this bacterium for decades to investigate fundamental biological processes, including DNA replication, gene regulation, protein synthesis, bacterial metabolism, and genetic evolution. It is also widely used in molecular cloning, recombinant protein production, genetic engineering, and synthetic biology.

One of the most interesting characteristics of E. coli is its remarkable diversity. Some strains are harmless members of the normal intestinal microbiota, others behave as opportunistic pathogens when they enter normally sterile body sites, and certain strains have acquired specific genes that enable them to produce toxins or cause disease through specialized mechanisms.

These differences make E. coli important not only in medical and veterinary microbiology but also in food safety, environmental microbiology, antimicrobial resistance research and biotechnology.

Fig. 1. Escherichia coli bacteria showing rod-shaped cells and surface appendages. AI-generated illustration inspired by scanning electron microscopy.

General characteristics of Escherichia coli

E. coli is a facultatively anaerobic bacterium, meaning that it can grow in the presence or absence of oxygen. Many strains are motile through peritrichous flagella, although non-motile strains also occur. The bacterium does not form endospores and generally grows well at temperatures close to the body temperature of mammals. Like other Gram-negative bacteria, E. coli has an inner membrane, a thin peptidoglycan layer and an outer membrane containing lipopolysaccharide (LPS). This cell envelope provides structural protection and influences interactions with antimicrobial substances and the host immune system.

Most E. coli strains ferment lactose and produce characteristic pink colonies on MacConkey agar. On eosin methylene blue (EMB) agar, typical strong lactose-fermenting strains may produce colonies with a metallic green sheen. However, some strains differ in their biochemical characteristics, and these observations alone cannot establish whether an isolate is pathogenic. Under favourable laboratory conditions, certain E. coli strains can divide approximately every 20 minutes. Their relatively simple nutritional requirements, rapid growth and well-characterized genetics have made them especially useful for experimental research.

Discovery and history of Escherichia coli

The history of E. coli began in 1885, when Theodor Escherich, a German-Austrian paediatrician, described bacteria isolated from the intestinal contents of infants. The organism was initially named Bacterium coli commune, reflecting its association with the colon. It was subsequently placed in the genus Escherichia, named in honour of Theodor Escherich, and became known as Escherichia coli. During the twentieth century, E. coli became one of the most important organisms in experimental biology. Research involving E. coli and its bacteriophages contributed to major discoveries in bacterial genetics, DNA replication, gene expression and the regulation of cellular processes.

The development of recombinant DNA technology further increased its importance. Scientists learned to introduce foreign genes into laboratory strains and use the bacteria to produce specific proteins. This contributed to the development of recombinant human insulin and many other biological products. Another important milestone occurred in 1997, when researchers published the complete genome sequence of the laboratory strain E. coli K-12 MG1655. This genome became an important reference for understanding bacterial physiology, metabolism and genetic organization. Today, E. coli remains a valuable organism for research in microbiology, molecular genetics, biotechnology, evolutionary biology and synthetic biology.

Classification and diversity of Escherichia coli

Escherichia coli belongs to the genus Escherichia, which also includes other recognized species such as E. albertii and E. fergusonii. These are genetically related organisms but are not different strains of E. coli. Within E. coli, extensive genetic diversity exists among strains. Researchers commonly distinguish these strains using serotypes, phylogenetic groups, sequence types and disease-associated characteristics.

Serotypes

Traditional E. coli serotyping is primarily based on differences in bacterial surface antigens. The O antigen is associated with lipopolysaccharide in the outer membrane, while the H antigen is associated with flagella. Capsular K antigens may also be relevant in certain classification systems. For example, E. coli O157:H7 is a well-known serotype associated with Shiga toxin-producing infections. However, many other serotypes can cause disease, and the presence of a particular O or H antigen does not necessarily establish pathogenicity. Several non-O157 serogroups, including O26, O45, O103, O111, O121 and O145, are also important in human Shiga toxin-producing infections.

Phylogenetic groups

Genomic studies have identified several major E. coli phylogenetic groups, commonly including A, B1, B2, C, D, E, F and G. These groups describe evolutionary relationships rather than specific diseases. Some are more frequently associated with particular ecological habitats or pathogenic characteristics. For example, many extraintestinal pathogenic E. coli strains belong to phylogroup B2. However, pathogenic strains can occur in different phylogenetic groups, and no major phylogroup should automatically be considered entirely harmless or pathogenic.

Sequence types

Multilocus sequence typing (MLST) classifies bacterial isolates according to the allelic profiles of selected housekeeping genes. These profiles are assigned sequence types, commonly abbreviated as STs. One important example is E. coli ST131, a globally distributed lineage associated with extraintestinal infections and antimicrobial resistance. Sequence typing helps researchers compare bacterial populations across different countries, hosts and environments. Whole-genome sequencing provides even greater resolution for investigating closely related strains and their transmission.

Pathotypes

For medical and veterinary microbiology, E. coli is frequently classified according to its disease-causing mechanisms. These groups are known as pathotypes. Pathotypes are not separate species. Instead, they represent strains with particular combinations of virulence factors and characteristic disease associations. Two broad categories are especially important: intestinal pathogenic E. coli, which primarily causes gastrointestinal disease, and extraintestinal pathogenic E. coli, which causes infections outside the intestinal tract.

Intestinal pathogenic Escherichia coli

Intestinal pathogenic E. coli, also called diarrhoeagenic E. coli (DEC), includes several pathotypes that cause gastrointestinal disease through different mechanisms. The major groups are enterotoxigenic E. coli (ETEC), enteropathogenic E. coli (EPEC), Shiga toxin-producing E. coli (STEC), enteroinvasive E. coli (EIEC), enteroaggregative E. coli (EAEC) and diffusely adherent E. coli (DAEC).

Enterotoxigenic E. coli (ETEC)

Enterotoxigenic E. coli is an important cause of watery diarrhoea, particularly among young children in endemic regions and travellers visiting areas where the infection is common. ETEC colonizes the small intestine using specialized adhesins, often called colonization factors. These structures allow the bacteria to attach to intestinal epithelial cells and resist removal through normal intestinal movement. After colonization, ETEC produces one or both of two major enterotoxins: heat-labile toxin (LT) and heat-stable toxin (ST). LT increases intracellular cyclic AMP signalling, whereas the clinically important STa toxin activates guanylate cyclase C and increases cyclic GMP signalling. These changes disturb intestinal electrolyte transport and promote water secretion into the intestinal lumen. The resulting illness is usually characterized by watery diarrhoea, often without extensive destruction of the intestinal epithelium.

Enteropathogenic E. coli (EPEC)

Enteropathogenic E. coli is associated with diarrhoea, especially in infants and young children. EPEC causes disease by attaching closely to intestinal epithelial cells and producing characteristic attaching-and-effacing lesions. These lesions involve the loss of intestinal microvilli and rearrangement of the host-cell actin cytoskeleton. An important virulence mechanism involves a type III secretion system encoded by the locus of enterocyte effacement (LEE) pathogenicity island. This specialized apparatus transfers bacterial effector proteins into host cells. One of these proteins, the translocated intimin receptor (Tir), becomes inserted into the host-cell membrane and interacts with the bacterial outer-membrane adhesin intimin. This interaction promotes intimate attachment and the formation of actin-rich pedestal-like structures beneath the bacteria. EPEC strains are commonly divided into typical and atypical EPEC. Typical EPEC carries the EAF plasmid encoding bundle-forming pili, whereas atypical EPEC lacks this defining plasmid. Their epidemiology and clinical significance may differ, and detecting atypical EPEC does not always establish that it is responsible for a patient's symptoms.

Shiga toxin-producing E. coli (STEC)

Shiga toxin-producing E. coli is one of the most important foodborne bacterial pathogens because certain strains can cause severe intestinal disease and life-threatening complications. STEC strains produce Shiga toxins, principally classified as Stx1 and Stx2. These toxins interfere with protein synthesis in susceptible host cells and can cause tissue injury. E. coli O157:H7 is a well-known STEC serotype, but numerous non-O157 serotypes also cause infections. Symptoms may include severe abdominal cramps, diarrhoea and bloody diarrhoea. Some patients develop haemorrhagic colitis, while a proportion progress to haemolytic uraemic syndrome (HUS).

HUS is characterized by three major abnormalities: microangiopathic haemolytic anaemia, thrombocytopenia and acute kidney injury. It is particularly concerning in young children, although adults can also develop severe complications. The genes encoding Shiga toxins are commonly carried by temperate bacteriophages integrated into the bacterial genome. Different toxin subtypes vary in their biological characteristics, with certain Stx2 subtypes associated with a greater risk of severe disease. The term enterohaemorrhagic E. coli (EHEC) is often used for STEC strains associated with haemorrhagic colitis and HUS. However, STEC is the broader classification based on Shiga toxin production, and the two terms are not exact synonyms.

Enteroinvasive E. coli (EIEC)

Enteroinvasive E. coli causes intestinal disease through mechanisms closely related to those used by Shigella. EIEC can invade colonic epithelial cells, escape from the initial membrane-bound compartment and multiply within the host-cell cytoplasm. The bacteria can spread between neighbouring cells through actin-based movement, contributing to epithelial damage and inflammation. Infection may produce abdominal cramps, fever and inflammatory diarrhoea. Severe cases can resemble bacillary dysentery. EIEC and Shigella are genetically closely related, and some routine molecular diagnostic tests cannot reliably distinguish between them.

Enteroaggregative E. coli (EAEC)

Enteroaggregative E. coli is associated with acute and persistent diarrhoea in children and adults, including travellers. EAEC strains are known for their characteristic aggregative adherence to epithelial cells, often described as a stacked-brick arrangement. Many strains possess aggregative adherence fimbriae and other factors that support intestinal colonization and biofilm formation. The AggR transcriptional regulator controls several virulence-associated genes in many typical EAEC strains. However, EAEC is a genetically heterogeneous group. Different strains may carry different combinations of adhesins, toxins and other virulence factors. Some EAEC strains are also detected in asymptomatic individuals. Therefore, identification of an EAEC-associated genetic marker does not always establish that the organism is responsible for the illness.

Diffusely adherent E. coli (DAEC)

Diffusely adherent E. coli includes strains that display a diffuse pattern of attachment to cultured epithelial cells. Certain DAEC strains possess Afa/Dr family adhesins that interact with host-cell receptors and may contribute to altered epithelial functions and inflammation. DAEC has been associated with diarrhoea, particularly in some groups of children. However, its pathogenic role is less consistently established than that of ETEC or STEC. The diversity within this group and its detection in asymptomatic individuals make clinical interpretation challenging.

Extraintestinal pathogenic Escherichia coli

Not all pathogenic E. coli strains cause gastrointestinal disease. Some can produce infections outside the intestinal tract and are collectively described as extraintestinal pathogenic E. coli (ExPEC). Many ExPEC strains may live in the intestinal microbiota without producing symptoms. Disease can develop when these bacteria reach other anatomical sites where they can attach, multiply and overcome local immune defences.

Uropathogenic E. coli (UPEC)

Uropathogenic E. coli is the leading bacterial cause of urinary tract infections, including cystitis and pyelonephritis. Most infections begin when intestinal E. coli reach the periurethral region and subsequently ascend into the urinary tract. UPEC possesses specialized adhesins that facilitate attachment to urinary tract tissues. Type 1 fimbriae, particularly the FimH adhesin, play an important role in attachment to bladder epithelial cells. P fimbriae and other adhesins may contribute to colonization of urinary tract tissues. Some UPEC strains can invade superficial bladder epithelial cells and form intracellular bacterial communities. These structures have been investigated as possible contributors to persistence and recurrent infections. Other important virulence-associated factors include iron-acquisition systems, capsules, toxins and mechanisms that protect bacteria from host immune responses. However, recurrent urinary tract infections can result from different mechanisms, and they should not all be attributed to intracellular bacterial persistence.

Neonatal meningitis-associated E. coli (NMEC)

Certain E. coli strains can cause serious infections in newborn infants, including meningitis. These infections may develop when bacteria enter the bloodstream and subsequently cross barriers protecting the central nervous system. The K1 polysaccharide capsule is commonly associated with neonatal meningitis strains. It contributes to resistance against host immune defences and supports bacterial survival during systemic infection. Other factors, including adhesins, invasion-associated proteins and iron-acquisition mechanisms, may also contribute to disease development. Neonatal E. coli meningitis is a serious condition requiring urgent medical treatment.

Bloodstream infection and sepsis

E. coli is also an important cause of bloodstream infections and sepsis. In many patients, bacteria reach the bloodstream from an existing urinary tract or abdominal infection. Severe infections may trigger widespread inflammatory and physiological disturbances. Sepsis occurs when the host response to infection becomes dysregulated and leads to life-threatening organ dysfunction. The clinical outcome depends on the infection source, bacterial characteristics, underlying health conditions and the effectiveness of treatment.

Pathogenic E. coli in animals

Pathogenic E. coli also causes several important diseases in livestock, poultry and companion animals. In calves and piglets, certain ETEC strains produce diarrhoea through colonization factors and enterotoxins. Porcine post-weaning diarrhoea is frequently associated with ETEC strains carrying F4 or F18 fimbrial adhesins. Oedema disease in pigs is associated with particular Shiga toxin-producing strains, especially those producing Stx2e. These strains can cause vascular injury and oedematous lesions. Avian pathogenic E. coli (APEC) is associated with colibacillosis in poultry, while certain E. coli strains cause mastitis in dairy cattle. These diseases are important in veterinary medicine because they affect animal health, production performance, antimicrobial use and farm management. However, their virulence mechanisms and epidemiological characteristics are not necessarily identical to those of human pathogenic strains.

Natural habitats and reservoirs of E. coli

The gastrointestinal tract of humans and many animals is the principal natural habitat of E. coli. In healthy individuals, commensal strains commonly exist as part of the intestinal microbiota. Their abundance varies with age, diet, host species, antibiotic exposure, inflammation and interactions with other microorganisms. Although E. coli is a familiar intestinal bacterium, it generally represents a relatively small proportion of the microbial community in many healthy adults, where obligately anaerobic bacteria are more abundant. Cattle and other ruminants are particularly important reservoirs for many STEC strains. These animals may carry pathogenic strains without developing obvious disease and can shed the bacteria through faeces.

Pigs, poultry, wildlife and companion animals can also harbour diverse E. coli populations, including strains carrying virulence or antimicrobial resistance genes. Outside animal hosts, E. coli may survive for varying periods in water, manure, soil, sediments and contaminated surfaces. Its persistence depends on environmental conditions, including temperature, moisture and nutrient availability. Because of its association with faecal material, E. coli is widely used as an indicator organism in water-quality monitoring. However, detecting E. coli in water does not automatically mean that a pathogenic strain is present. It primarily indicates possible faecal contamination and the need to consider potential exposure to enteric microorganisms.

Transmission of E. coli

The transmission of E. coli depends strongly on the pathotype and disease involved. Intestinal pathogenic strains commonly spread through the faecal–oral route. Infection may occur through contaminated food, drinking water, hands, surfaces or direct contact with infected animals. For STEC, important transmission sources include undercooked beef, unpasteurized milk, contaminated vegetables, sprouts and untreated water. Contact with cattle or environments contaminated by animal faeces can also result in infection. Human-to-human transmission is possible, particularly when close contact and inadequate hygiene allow faecal–oral spread.

ETEC infections are frequently associated with contaminated food or drinking water in areas where sanitation is inadequate. Extraintestinal infections may follow different pathways. Many urinary tract infections arise from strains already present in the patient's own intestinal microbiota. These bacteria can reach the urinary tract and establish an infection without a separate foodborne exposure. Maternal or perinatal acquisition can also be important in neonatal E. coli infections. These distinctions explain why preventing foodborne diarrhoea and preventing urinary tract infections require different approaches.

How E. coli causes disease

The pathogenicity of E. coli depends on a combination of bacterial virulence factors and host susceptibility. There is no single mechanism responsible for all E. coli infections. In intestinal infections, the process often begins when pathogenic bacteria enter the digestive tract, reach a suitable colonization site and attach to host tissues. Once established, they may release toxins, alter intestinal transport, modify host-cell signalling or invade epithelial cells. ETEC primarily causes secretory diarrhoea through enterotoxin activity. EPEC changes the intestinal epithelial surface by producing attaching-and-effacing lesions. EIEC invades epithelial cells, whereas STEC produces toxins that can affect tissues beyond the intestine.

The mechanisms of extraintestinal infection differ. ExPEC strains may initially colonize the intestine without causing symptoms and later enter normally protected sites, such as the urinary tract or bloodstream. Once established, these bacteria may use adhesins, capsules, iron-acquisition systems and other factors to survive and multiply in host tissues. The outcome depends not only on bacterial virulence genes but also on host age, immune function, underlying disease, microbiota composition and the site of infection.

Major virulence factors of E. coli

The pathogenic potential of E. coli is associated with several bacterial structures and molecules. Their presence and biological importance vary considerably between strains and pathotypes.

Adhesins and fimbriae

Adhesins allow bacteria to attach to host tissues and are often associated with fimbriae or other surface structures. In UPEC, type 1 fimbriae and their FimH adhesin contribute to bladder colonization, while P fimbriae may facilitate attachment to tissues of the upper urinary tract. ETEC uses colonization factors to attach to the small intestinal epithelium. EPEC and many STEC strains possess intimin-associated attachment mechanisms. Successful attachment is often an important early step because it helps bacteria resist removal and establish infection at the appropriate anatomical site.

Type III secretion systems

Type III secretion systems are specialized bacterial structures that transfer effector proteins directly into host cells. In EPEC and many STEC strains, a secretion system encoded by the LEE pathogenicity island modifies host-cell signalling and the actin cytoskeleton. These changes contribute to the formation of attaching-and-effacing lesions and demonstrate how bacteria can manipulate host cells without necessarily invading them. EIEC uses a different invasion-associated type III secretion system related to that found in Shigella.

Capsular polysaccharides

Capsules form protective layers around certain E. coli strains. Some capsules reduce susceptibility to complement-mediated killing and other host immune mechanisms. The K1 capsule is particularly important in neonatal meningitis-associated strains because it contributes to bacterial survival during systemic infection.

Iron-acquisition systems

Iron is essential for bacterial growth, but freely available iron is limited within the host because it is bound by proteins. Many pathogenic E. coli strains possess specialized iron-acquisition mechanisms, including siderophores that bind iron and facilitate its uptake. These systems are particularly important for ExPEC strains growing in iron-restricted environments such as the urinary tract and bloodstream.

Lipopolysaccharide

Lipopolysaccharide is a major component of the Gram-negative bacterial outer membrane. Its lipid A component can activate innate immune signalling and contribute to inflammatory responses. During severe systemic infections, excessive inflammatory responses associated with LPS and other microbial components can contribute to organ dysfunction. However, LPS should not be considered the primary disease-causing factor in every E. coli infection because different pathotypes rely on different mechanisms.

Virulence plasmids and bacteriophages

Many important E. coli virulence genes are carried on mobile genetic elements, including plasmids and bacteriophages. For example, genes encoding Shiga toxins are commonly carried by temperate bacteriophages, while several ETEC colonization factors and enterotoxins are plasmid-associated. The acquisition or loss of these elements can alter a bacterial strain's pathogenic potential. This genetic flexibility is one of the major reasons why E. coli populations display such extensive biological diversity.

Important toxins produced by E. coli

Different pathogenic E. coli strains produce toxins with distinct molecular targets and clinical effects.

Heat-labile enterotoxin (LT)

Heat-labile enterotoxin is mainly associated with ETEC. It belongs to the AB5 family of bacterial toxins and is functionally related to cholera toxin. After binding to intestinal epithelial cells and entering them, its enzymatically active component modifies the host Gs protein, leading to persistent activation of adenylate cyclase signalling. This increases intracellular cyclic AMP and alters intestinal electrolyte transport, promoting fluid secretion and watery diarrhoea.

Heat-stable enterotoxin (ST)

The clinically important STa toxin is a small peptide produced by certain ETEC strains. STa binds to guanylate cyclase C receptors on intestinal epithelial cells and increases intracellular cyclic GMP. This affects electrolyte transport and promotes water accumulation within the intestine. Unlike Shiga toxin, STa primarily produces diarrhoea by modifying intestinal secretory processes rather than directly causing vascular injury.

Shiga toxins (Stx1 and Stx2)

Shiga toxins are among the most clinically important virulence factors associated with severe E. coli infections. They belong to the AB5 toxin family and act as ribosome-inactivating proteins. After entering susceptible cells, the enzymatically active component removes a specific adenine residue from ribosomal RNA. This disrupts protein synthesis and can lead to cellular injury. The genes encoding Shiga toxins are generally associated with bacteriophages integrated into the bacterial genome. Shiga toxins can affect susceptible tissues, including the microvascular endothelium. Their effects on the renal microvasculature are particularly important in the development of haemolytic uraemic syndrome. Different toxin subtypes have different biological properties, and certain Stx2 subtypes are associated with a greater risk of severe disease.

Alpha-haemolysin (HlyA)

Alpha-haemolysin is a pore-forming toxin produced by certain E. coli strains, particularly some ExPEC lineages. It can damage host-cell membranes and contribute to inflammatory responses and tissue injury. However, it is not universally present in pathogenic E. coli, and its contribution to infection varies between strains and anatomical sites.

Cytotoxic necrotizing factor 1 (CNF1)

CNF1 modifies members of the Rho family of small GTPases, which regulate several cellular functions, including cytoskeletal organization. Through these interactions, CNF1 can alter host-cell behaviour and contribute to processes involved in infection. It has been identified in certain extraintestinal pathogenic E. coli strains, although its role differs between clinical settings.

Diseases caused by E. coli

E. coli infections can range from mild intestinal illness to serious systemic disease.

Gastrointestinal infections

Diarrhoeagenic E. coli pathotypes produce different forms of intestinal disease depending on their virulence mechanisms. ETEC typically causes watery diarrhoea, while EPEC may cause diarrhoea associated with damage to the intestinal absorptive surface. EAEC has been associated with acute and persistent diarrhoea, whereas EIEC can produce inflammatory diarrhoea resembling dysentery. STEC infection may cause severe abdominal pain, bloody diarrhoea and haemorrhagic colitis. A proportion of STEC infections progress to HUS, which can cause severe kidney injury and other complications.

Urinary tract infections

UPEC causes a large proportion of community-acquired urinary tract infections. Cystitis commonly produces painful urination, increased urinary frequency, urgency and lower abdominal discomfort. When infection reaches the kidneys, pyelonephritis may develop, producing fever, flank pain and systemic symptoms. Some patients experience recurrent infections, which may involve reinfection, host susceptibility or bacterial persistence.

Bloodstream infection and sepsis

E. coli is an important cause of bloodstream infections, often originating from urinary tract or abdominal infections. Severe infection may progress to sepsis, in which a dysregulated host response leads to life-threatening organ dysfunction. Older adults, hospitalized patients, individuals with underlying diseases and people with impaired immune function may be particularly vulnerable.

Neonatal meningitis

Certain E. coli strains can cause meningitis in newborn infants. The infection may involve bacterial entry into the bloodstream followed by invasion of the central nervous system. Neonatal meningitis can cause severe complications and requires urgent diagnosis and antimicrobial treatment.

Diseases in animals

In veterinary medicine, pathogenic E. coli is associated with diarrhoea in newborn calves and piglets, post-weaning diarrhoea and oedema disease in pigs, colibacillosis in poultry and certain forms of bovine mastitis. These diseases are important because they affect animal welfare, production performance, antimicrobial use and economic outcomes. The responsible strains and their virulence mechanisms vary, so animal-associated E. coli diseases should not be regarded as direct equivalents of human infections.

Diagnosis of E. coli infections

Accurate diagnosis depends on the suspected disease and the type of clinical sample. For intestinal infections, stool samples may be examined using bacterial culture, toxin-detection methods or molecular assays. A major diagnostic challenge is that commensal E. coli is normally present in the intestine. Therefore, isolating E. coli from a stool sample does not automatically establish that it caused the patient's diarrhoea. For suspected STEC infection, laboratory testing should detect Shiga toxins or their encoding genes. Culture remains valuable because it allows bacterial isolates to be characterized further.

Multiplex PCR panels can detect markers associated with several diarrhoeagenic pathotypes. However, the presence of a particular marker needs to be interpreted alongside the clinical findings. Urinary tract infections may be investigated using urine culture and antimicrobial susceptibility testing, particularly in complicated or recurrent cases. Blood cultures are important for diagnosing bloodstream infections, while cerebrospinal fluid analysis and culture are used when bacterial meningitis is suspected. Additional methods include biochemical identification systems, MALDI-TOF mass spectrometry, PCR and whole-genome sequencing. Whole-genome sequencing is increasingly used in public health surveillance and research because it can identify bacterial lineages, resistance genes, virulence-associated determinants and relationships between isolates.

Treatment and clinical management

Treatment depends on the type of E. coli infection, its severity and the susceptibility of the infecting strain. Most uncomplicated intestinal infections improve with supportive care, particularly adequate fluid and electrolyte replacement. Antibiotics are not routinely required for every intestinal E. coli infection. Their use depends on the suspected pathotype, clinical presentation, underlying health conditions and antimicrobial resistance patterns. An important exception concerns suspected or confirmed STEC infection. Antibiotics should generally be avoided because their use may increase the risk of HUS. Antimotility medications should also be avoided in STEC infection and bloody diarrhoea.

Patients with severe dehydration or complications may require hospital care and intravenous fluids. HUS requires urgent specialist assessment and supportive treatment, which may include renal replacement therapy in severe cases. Extraintestinal infections often require antimicrobial treatment. Antibiotic selection depends on the infection site, clinical severity, patient characteristics and susceptibility profile. Severe pyelonephritis, bloodstream infections and meningitis may require hospitalization and intravenous antimicrobial treatment. The increasing prevalence of antimicrobial-resistant E. coli makes susceptibility testing particularly important in serious or complicated infections.

Antimicrobial resistance in E. coli

Antimicrobial resistance is one of the most important public health challenges associated with E. coli. The bacterium can develop resistance through chromosomal mutations and the acquisition of resistance genes carried on plasmids and other mobile genetic elements. Extended-spectrum beta-lactamase-producing E. coli strains, commonly called ESBL-producing E. coli, are particularly important because they can resist many penicillins and extended-spectrum cephalosporins. Genes belonging to the CTX-M family have played a major role in the global spread of ESBL-mediated resistance. Some strains also carry carbapenemase genes, including those encoding NDM, KPC or OXA-48-like enzymes. These mechanisms can substantially reduce treatment options.

Resistance to fluoroquinolones often involves mutations affecting bacterial DNA gyrase and topoisomerase IV, sometimes combined with plasmid-mediated resistance mechanisms. Certain successful bacterial lineages have attracted particular attention. E. coli ST131, for example, has contributed to the global spread of extraintestinal infections associated with fluoroquinolone resistance and ESBL production. However, antimicrobial resistance is not restricted to a single sequence type or ecological reservoir. Resistant E. coli populations have been detected in humans, livestock, companion animals, wildlife, wastewater and environmental samples. Understanding how resistant strains and their genetic elements move between these settings remains an important area of One Health research.

E. coli from a One Health perspective

E. coli is particularly relevant to One Health because it inhabits interconnected human, animal and environmental ecosystems. Many commensal and pathogenic strains circulate among humans and animals, while antimicrobial-resistant bacteria or their genetic elements may move through food systems, wastewater, agricultural environments and direct contact. In livestock production, E. coli may be shed through faeces and enter manure, soil and water. Food products can become contaminated during production or processing. Companion animals may also carry antimicrobial-resistant E. coli strains, including lineages genetically related to those found in humans.

However, genetic similarity alone does not establish whether transmission occurred from animals to humans, from humans to animals or through a common source. Integrated surveillance involving clinical, veterinary, food-chain and environmental samples can improve our understanding of these relationships. Combining bacterial culture, genomic sequencing, antimicrobial susceptibility testing and epidemiological information allows researchers to investigate transmission networks and emerging resistance patterns. Responsible antimicrobial use, improved sanitation, food safety, infection prevention and environmental management are all important components of One Health strategies involving E. coli.

Vaccines against E. coli

Developing vaccines against E. coli is challenging because pathogenic strains are genetically diverse and cause different diseases through different mechanisms. A vaccine designed to prevent ETEC diarrhoea may need to stimulate intestinal immune responses against colonization factors and enterotoxins. In contrast, vaccines targeting extraintestinal infections may focus on capsular polysaccharides, O antigens or other factors associated with systemic disease. As of October 2026, no human vaccine is licensed specifically to prevent E. coli infections. ETEC vaccine development has progressed through several clinical studies. One important candidate is ETVAX, an oral inactivated whole-cell vaccine containing ETEC antigens and a toxin-related component. A phase 2b trial involving young children in The Gambia was published in 2026. The vaccine was found to be immunogenic and had an acceptable safety profile. However, it did not meet the prespecified primary efficacy endpoint. Some secondary and exploratory analyses suggested potential protection against particular forms of ETEC-associated diarrhoea, supporting further investigation.

Another important research programme involved ExPEC9V, an investigational vaccine targeting extraintestinal pathogenic E. coli. In February 2025, its phase 3 E.mbrace study was discontinued after an independent monitoring committee determined that the vaccine did not provide sufficient protection against invasive E. coli disease. No vaccine-related safety signal was identified as the reason for discontinuation. These studies demonstrate both the progress and the difficulties of developing effective vaccines against such a diverse bacterial species. Veterinary vaccines against selected E. coli-associated diseases are already used in some livestock and poultry production systems. Their targets, formulations and availability differ by animal species, disease and country.

Prevention and control

Preventing E. coli infection requires measures appropriate to the different transmission pathways. For foodborne intestinal infections, safe food handling, clean drinking water, proper sanitation and prevention of faecal contamination are essential. Meat should be cooked thoroughly, and unpasteurized milk and other high-risk products should be avoided. Raw foods should be handled separately from ready-to-eat foods to reduce cross-contamination. Good hand hygiene is especially important after using the toilet, handling animals, changing diapers or preparing raw animal products. On farms, biosecurity, appropriate manure management and prevention of contamination of feed, water and food-production environments can help reduce bacterial transmission. Healthcare-associated infections require suitable infection prevention practices, including hand hygiene, appropriate catheter management and responsible antimicrobial use. Because E. coli causes several biologically different diseases, no single preventive intervention can eliminate every form of infection.

E. coli in intestinal microbiome research

The relationship between E. coli and the intestinal microbiota is an important area of current research. Commensal E. coli populations interact with other intestinal microorganisms, host immune defences and the chemical environment of the gut. Their abundance may change with age, diet, antibiotic exposure, inflammation and disturbances in the microbial community. In healthy adults, E. coli generally represents a relatively small proportion of the intestinal microbiota. However, its abundance may increase under certain conditions, particularly when inflammation changes nutrient availability and the intestinal environment. Members of the family Enterobacteriaceae can benefit from some of these changes. For example, increased availability of certain electron acceptors during intestinal inflammation may favour the expansion of facultatively anaerobic bacteria.

However, an increase in E. coli abundance does not necessarily mean that the bacterium caused the underlying disease. In some circumstances, bacterial expansion may be a consequence of changes in the intestinal environment rather than the initial cause. An interesting example involves adherent-invasive E. coli (AIEC), which has been studied in relation to Crohn's disease. AIEC strains possess functional characteristics associated with adhesion, epithelial-cell invasion and survival within macrophages. However, AIEC remains a research-defined group rather than a uniformly established routine diagnostic pathotype. Its association with Crohn's disease does not prove that it is the sole or primary cause of the condition. Another important issue concerns microbiome sequencing.

Standard 16S rRNA sequencing often cannot reliably distinguish E. coli from closely related Shigella populations. Even full-length 16S rRNA sequencing may not provide sufficient resolution to identify pathogenic E. coli strains. Therefore, detecting an increase in Escherichia/Shigella or Enterobacteriaceae in microbiome data does not establish the presence of a toxin-producing or clinically pathogenic E. coli strain. Shotgun metagenomics, strain-resolved genomic analysis, bacterial isolation and functional assays can provide additional information about strain diversity and virulence potential. Researchers are also investigating how microbial metabolites, nutrient competition and immune responses affect E. coli colonization and persistence. These approaches are helping scientists understand why some E. coli strains remain harmless intestinal residents while others become opportunistic or established pathogens.

E. coli as a model organism in molecular biology and biotechnology

Apart from its importance in infectious disease, E. coli is one of the most widely used organisms in molecular biology and biotechnology. Laboratory strains such as K-12 and its derivatives have been extensively characterized and are routinely used because of their rapid growth, relatively simple nutritional requirements and genetic tractability. Research involving E. coli has contributed to fundamental discoveries in DNA replication, transcription, translation, gene regulation and bacterial genetics. The bacterium is commonly used for molecular cloning, plasmid propagation, gene expression and recombinant protein production. Engineered E. coli strains can produce enzymes, research proteins, selected pharmaceutical products and other valuable biological compounds.

Synthetic biology has further expanded these applications by allowing researchers to design genetic circuits, modify metabolic pathways and engineer bacteria to carry out particular biological functions. However, E. coli is not suitable for every biotechnology application. Standard bacterial expression systems cannot perform all the complex post-translational modifications required by some eukaryotic proteins. Certain recombinant proteins may also form insoluble aggregates, and purification processes must address bacterial contaminants such as endotoxin. Despite these limitations, the extensive scientific knowledge available for E. coli and the wide range of genetic tools developed for it make the bacterium especially valuable in experimental and industrial microbiology.

Current research on Escherichia coli

Research on E. coli continues to expand across infectious disease, microbial ecology, evolutionary biology, genomics and biotechnology. One major area focuses on the emergence and evolution of pathogenic strains. Comparative genomics helps researchers investigate how different bacterial lineages acquire virulence genes, toxins, adhesins and antimicrobial resistance determinants. Horizontal gene transfer plays an important role in this process. Plasmids, bacteriophages and other mobile genetic elements can introduce new biological functions into bacterial populations. A well-known example is the 2011 European outbreak caused by E. coli O104:H4. The outbreak strain combined enteroaggregative characteristics with Shiga toxin production, demonstrating how different virulence mechanisms can occur within the same bacterial lineage.

Antimicrobial resistance is another major research priority. Researchers are studying the spread of successful resistant clones, the movement of resistance plasmids and the environmental and host factors that influence their persistence. Whole-genome sequencing has transformed outbreak investigations and population-level surveillance. Long-read sequencing is also helping scientists resolve complex plasmids and other genomic regions that may be difficult to characterize using short-read sequencing alone. In microbiome research, increasing attention is being given to strain-level differences rather than measuring E. coli simply as a single bacterial species. This is important because commensal and pathogenic strains can occupy similar habitats while possessing very different biological characteristics. Alternative therapeutic strategies are also being investigated. These include bacteriophage-based interventions, anti-virulence compounds, inhibitors of bacterial adhesion and approaches targeting microbial competition or intestinal colonization.

For UPEC, the development of FimH-targeting anti-adhesion compounds is one example of research aimed at interfering with bacterial attachment rather than directly killing the bacteria. Vaccine research remains active, particularly for ETEC and ExPEC, although recent clinical trials have shown that generating effective protection against genetically diverse E. coli populations remains challenging. In biotechnology, researchers continue to develop improved protein-expression systems, genome-editing methods and engineered metabolic pathways. The broad scientific importance of E. coli comes from these different biological roles. It is a normal member of the intestinal microbiota, an important human and animal pathogen, a major organism in antimicrobial resistance research and one of the most useful experimental systems for studying bacterial biology.

References

1. Blattner, F. R., Plunkett, G., III, Bloch, C. A., Perna, N. T., Burland, V., Riley, M., Collado-Vides, J., Glasner, J. D., Rode, C. K., Mayhew, G. F., Gregor, J., Davis, N. W., Kirkpatrick, H. A., Goeden, M. A., Rose, D. J., Mau, B., & Shao, Y. (1997). The complete genome sequence of Escherichia coli K-12. Science, 277(5331), 1453–1462.https://doi.org/10.1126/science.277.5331.1453

2. Centers for Disease Control and Prevention. (2024, May 14). Information for clinicians. https://www.cdc.gov/ecoli/hcp/guidance/

3. Centers for Disease Control and Prevention. (2024, May 14). Treatment of E. coli infection. https://www.cdc.gov/ecoli/treatment/index.html

4. Croxen, M. A., Law, R. J., Scholz, R., Keeney, K. M., Wlodarska, M., & Finlay, B. B. (2013). Recent advances in understanding enteric pathogenic Escherichia coli. Clinical Microbiology Reviews, 26(4), 822–880.https://doi.org/10.1128/CMR.00022-13

5. Denamur, E., Clermont, O., Bonacorsi, S., & Gordon, D. (2021). The population genetics of pathogenic Escherichia coli. Nature Reviews Microbiology, 19(1), 37–54. https://doi.org/10.1038/s41579-020-0416-x

6. Flores-Mireles, A. L., Walker, J. N., Caparon, M., & Hultgren, S. J. (2015). Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. Nature Reviews Microbiology, 13(5), 269–284.https://doi.org/10.1038/nrmicro3432

7. Hossain, M. J., Secka, F., Sanyang, L. C., Taiwo, R., Okoh, E. C., Olubiyi, O. A., Drammeh, M., Richard, E. U., Balami, A. D., Drammeh, M., Jallow, S. J., Sonko, B., Ezedimbu-Michael, P., Obiaduo, J., Secka, O., Kaim, J., Sjöstrand, B., Lissmats, A., Carlin, N., ... Wierzba, T. F. (2026). Efficacy of ETVAX, a vaccine against enterotoxigenic Escherichia coli-positive diarrhoea in Gambian children: A double-blind, randomised, placebo-controlled, phase 2b trial. The Lancet Infectious Diseases, 26(6), 627–637.https://doi.org/10.1016/S1473-3099(25)00774-1

8. Johnson & Johnson. (2025, February 13). Johnson & Johnson statement on Phase 3 E.mbrace study.https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-phase-3-e-mbrace-study

9. Kaper, J. B., Nataro, J. P., & Mobley, H. L. T. (2004). Pathogenic Escherichia coli. Nature Reviews Microbiology, 2(2), 123–140.https://doi.org/10.1038/nrmicro818

10. Rostamian, M., Shahbazi, S., Chegene Lorestani, R., Nemati Zargaran, F., & Bahrami, Y. (2026). A 25-year landscape of Escherichia coli vaccine development: Systematic review of human clinical studies. npj Vaccines, 11, Article 151. https://doi.org/10.1038/s41541-026-01444-6

11. World Health Organization. (2018, February 7). E. coli. https://www.who.int/news-room/fact-sheets/detail/e-coli

12. World Health Organization. (2025). Global antibiotic resistance surveillance report 2025. https://www.who.int/publications/i/item/9789240116337

13. World Health Organization & Food and Agriculture Organization of the United Nations. (2018). Shiga toxin-producing Escherichia coli (STEC) and food: Attribution, characterization, and monitoring (Microbiological Risk Assessment Series No. 31). https://www.who.int/publications-detail-redirect/9789241514279

No comments:

Post a Comment

Contact Microbes World

Name

Email *

Message *